Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.

Progression with initial baricitinib 2 mg was numerically lower than with initial placebo ( figure 3C ); the proportion of patients showing no mTSS progression was also higher in the baricitinib 2 mg group compared with the placebo group at both 1 and 2 years, but these differences did not reach statistical significance. 10.1136/rmdopen-2019-000898.supp2 Supplementary data For all treatment groups, lower rates of change in mTSS were observed between years 1 and 2 (when all patients were on baricitinib therapies) than between baseline and year 1 ( figure 3 ).

also in 111,027 other papers